Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transplantation in refractory/relapsed lymphoma patients.

Trial Profile

Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transplantation in refractory/relapsed lymphoma patients.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2012

At a glance

  • Drugs Bendamustine (Primary) ; Cytarabine; Etoposide; Melphalan
  • Indications Chronic lymphocytic leukaemia; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms BeEAM
  • Most Recent Events

    • 01 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top